Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Interest Coverage Ratio: 2013-2025

Historic Interest Coverage Ratio for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to -19.07.

  • Coherus Oncology's Interest Coverage Ratio fell 15.04% to -19.07 in Q3 2025 from the same period last year, while for Sep 2025 it was -3.69, marking a year-over-year increase of 65.87%. This contributed to the annual value of -4.11 for FY2024, which is 17.96% up from last year.
  • Latest data reveals that Coherus Oncology reported Interest Coverage Ratio of -19.07 as of Q3 2025, which was up 4.55% from -19.98 recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Interest Coverage Ratio ranged from a high of 2.32 in Q4 2024 and a low of -29.63 during Q1 2021.
  • Over the past 3 years, Coherus Oncology's median Interest Coverage Ratio value was -9.76 (recorded in 2024), while the average stood at -11.45.
  • Examining YoY changes over the last 5 years, Coherus Oncology's Interest Coverage Ratio showed a top increase of 135.81% in 2024 and a maximum decrease of 431.73% in 2024.
  • Coherus Oncology's Interest Coverage Ratio (Quarterly) stood at -6.83 in 2021, then climbed by 19.63% to -5.49 in 2022, then fell by 18.26% to -6.49 in 2023, then surged by 135.81% to 2.32 in 2024, then decreased by 15.04% to -19.07 in 2025.
  • Its Interest Coverage Ratio stands at -19.07 for Q3 2025, versus -19.98 for Q2 2025 and -21.13 for Q1 2025.